<DOC>
	<DOCNO>NCT00622232</DOCNO>
	<brief_summary>The objective study determine long term safety tolerability additional infusion 10 billion VRX496 gene-modified CD4 T cell focus evaluate additional therapeutic benefit respect viral load CD4 count .</brief_summary>
	<brief_title>A Rollover Study Subjects Who Completed Participation VRX496-USA-05-002 Trial</brief_title>
	<detailed_description>The study conclude 's 9-month active phase . Subjects currently 15-year Long Term Follow-up Phase study . In keep recently release Guidance Monitoring For Delayed Adverse Events , state first 5 year subject undergo monitoring vector sequence every 6 month , subject visit clinic maximum 6 month interval blood test evaluate persistence vector sequence . Therefore first 5 year , subject 6 month visit safety assessment . For year 6 15 , subject contact phone mail . At contact , subject ask health status .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Ability willingness give write informed consent accordance institutional federal guideline comply investigational nature study related requirement . Subjects successfully complete participation VRX496USA05002 trial . Subjects initiate change new ARV regimen 3 month prior Entry Assessment eligible . Subjects ( 1 ) ARVs willing continue current therapy unchanged , ( 2 ) ARV willing remain ARVs duration trial i.e . 9 month . However , clinical need start change ARV therapy , permit . CD4 count decrease ≥25 % baseline main study . Viral load increase ≥ 1.0 log baseline main study ≥ 200,000 . Female subject reproductive potential positive serum B HCG Entry Assessment visit willing use reliable method barrier contraception . Are breastfeed . Subjects actively use injection drug substance abuse ( extensive alcohol narcotic use ) . Any medical condition ( ) , opinion investigator , would interfere subject 's ability participate adhere requirement protocol Active HIVrelated non HIVrelated illness Subjects additional cell product available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>treatment experience , complementary therapy</keyword>
</DOC>